Overview of Teriparatide
Teriparatide, a synthetic version of the parathyroid hormone, is a crucial therapy for individuals with osteoporosis who are at high risk of fractures. It is known for its ability to promote bone growth, making it a key player in the osteoporosis treatment market.
Market Size and Growth Projections
The market for teriparatide is integrated within the broader osteoporosis drugs market, which is expected to see significant growth in the coming years.
- The global osteoporosis drugs market is projected to reach USD 16.88 billion by 2025 and USD 21.28 billion by 2030, growing at a CAGR of 4.74% during the forecast period (2025-2030)[1].
- Specifically, the teriparatide acetate market was valued at USD 100 billion in 2023 and is expected to reach USD 147.75 billion by 2031, growing at a 5% CAGR from 2024 to 2031[5].
Regional Market Analysis
Largest Market
The largest market for osteoporosis drugs, including teriparatide, is North America. This region is home to a significant number of market players and has a high concentration of healthcare infrastructure, contributing to its dominance[1][4].
Fastest Growing Market
The Asia Pacific region is expected to be the fastest-growing market for osteoporosis drugs. This growth is driven by the increasing geriatric population, rising awareness of osteoporosis, and improving healthcare access in the region[1].
Key Drivers of Market Growth
Increasing Prevalence of Osteoporosis
The rising prevalence of osteoporosis, particularly among the geriatric population, is a major driver of the market. For instance, the prevalence of osteoporosis is estimated to be 15.9% in individuals aged 50 and over, with a significant gender disparity[1].
Product Approvals and Launches
Recent approvals and launches of innovative drugs, such as Apotex Corp.'s teriparatide injection and Radius Health, Inc.'s TYMLOS (abaloparatide), are expected to propel market growth. These new products enhance treatment options and improve patient outcomes[1][4].
Advances in Formulation and Manufacturing
Improvements in formulation and manufacturing technology for biopharmaceuticals, such as teriparatide, streamline production processes and ensure reliable supply and effectiveness. This enhances patient compliance and treatment outcomes[5].
Cost-Effectiveness and Pricing
Cost-Effectiveness Analysis
The cost-effectiveness of teriparatide is a critical factor in its market adoption. A study found that sequential teriparatide/zoledronic acid became cost-effective at age 80 with the cost of teriparatide reduced by 50%. Without this reduction, the incremental cost-effectiveness ratio (ICER) was significantly higher than the willingness-to-pay threshold[3].
Revenue Projections
The revenue for teriparatide is expected to grow substantially. For example, the revenue for Teriparatide LA by Shenzhen Salubris Pharmaceuticals is projected to reach an annual total of $108 million by 2036 globally[2].
Market Challenges
Adverse Effects
Despite its effectiveness, teriparatide faces challenges related to adverse effects. The fear of side effects among patients is a restraining factor for the market. Continuous research and development are necessary to mitigate these concerns[4].
Regulatory and Reimbursement Factors
Government initiatives and reimbursement policies play a significant role in the market growth of teriparatide. Favorable reimbursement rules can increase market penetration and accessibility of the drug[5].
Recent Developments
Apotex Corp.'s Teriparatide Injection
In November 2023, Apotex Corp. launched a teriparatide injection in the United States, designed for single-patient use. This product delivers 250 mcg/mL of teriparatide, providing 28 daily doses of 20 mcg per pen[1][4].
FDA Approval of TYMLOS
The FDA approved TYMLOS (abaloparatide) in December 2022 for increasing bone mineral density among men with osteoporosis at high risk for fracture. This approval by Radius Health, Inc. further expands treatment options[1].
Key Takeaways
- The teriparatide market is expected to grow significantly, driven by the increasing prevalence of osteoporosis and the launch of new products.
- North America is the largest market, while the Asia Pacific region is the fastest-growing.
- Cost-effectiveness and adverse effects are critical factors influencing market adoption.
- Recent approvals and launches of innovative drugs are propelling market growth.
- Advances in formulation and manufacturing technology are enhancing treatment outcomes and patient compliance.
FAQs
What is the projected market size for the osteoporosis drugs market by 2030?
The osteoporosis drugs market is expected to reach USD 21.28 billion by 2030, growing at a CAGR of 4.74% during the forecast period (2025-2030)[1].
Which region is expected to be the fastest-growing market for osteoporosis drugs?
The Asia Pacific region is expected to be the fastest-growing market for osteoporosis drugs[1].
What are the key drivers of the teriparatide market?
The key drivers include the increasing prevalence of osteoporosis, product approvals and launches, and advances in formulation and manufacturing technology[1][5].
How cost-effective is sequential teriparatide/zoledronic acid treatment?
Sequential teriparatide/zoledronic acid becomes cost-effective at age 80 with the cost of teriparatide reduced by 50%. Without this reduction, the ICER is significantly higher than the willingness-to-pay threshold[3].
What recent developments have impacted the teriparatide market?
Recent developments include the launch of Apotex Corp.'s teriparatide injection and the FDA approval of TYMLOS (abaloparatide) by Radius Health, Inc.[1][4].
Sources
- Mordor Intelligence: Osteoporosis Drugs Market - Report, Growth & Research.
- Pharmaceutical Technology: Risk Adjusted Net Present Value: What is the current valuation of Teriparatide LA.
- PMC: Cost-Effectiveness of Sequential Teriparatide/Zoledronic Acid.
- Precedence Research: Osteoporosis Treatment Companies | Forecast by 2033.
- Market Research Intellect: Teriparatide Acetate Market Size and Projections.
